Roundup litigation and court decisions are directly reshaping Bayer’s stock forecast for 2026 and beyond. On March 4, 2026, the company secured preliminary court approval for a $7.25 billion settlement that will pay out over 21 years—the largest component yet in resolving thousands of claims that glyphosate exposure caused non-Hodgkin’s lymphoma. This massive settlement, combined with approximately 65,000 claims still pending and 3,887 lawsuits in federal litigation, is forcing analysts to predict flat profit growth for 2026, negative free cash flow, and significant financial uncertainty for Bayer shareholders. The company has already spent more than $10 billion resolving Roundup cases, but this settlement does not end the litigation risk.
Beyond the settlement itself, two critical court decisions loom in 2026 that could dramatically alter Bayer’s financial trajectory. The Supreme Court will hear arguments on April 27, 2026, in *Monsanto v. Durnell*—a glyphosate liability case whose outcome in mid-June could either eliminate a substantial portion of remaining claims or trigger renewed litigation waves. Additionally, a Trump administration executive order issued in February 2026 declared glyphosate-based herbicides a matter of national security, potentially shielding manufacturers from liability.
Table of Contents
- The $7.25 Billion Settlement’s Direct Impact on Stock Forecasts
- Settlement Award Amounts and What Claimants Can Actually Expect
- The Massive Backlog of Pending Claims and Federal Litigation
- Analyst Ratings and Stock Price Targets in the Face of Litigation
- The Supreme Court Case That Could Reshape Everything
- The Trump Administration’s Glyphosate Executive Order and Liability Shield
- What to Watch Through 2026 and the Outlook Beyond
The $7.25 Billion Settlement’s Direct Impact on Stock Forecasts
The March 4, 2026 preliminary court approval of bayer‘s $7.25 billion settlement from the 22nd Judicial Circuit Court of Missouri serves as a watershed moment for the company’s financial guidance. Rather than clearing uncertainty, this settlement has prompted Bayer to forecast flat profit and sales growth for 2026—a striking contrast to typical pharmaceutical company forecasts. The company’s EBITDA guidance of €9.6 billion to €10.1 billion for 2026 falls against the analyst average of €9.75 billion, signaling that the market is pricing in significant settlement-related headwinds even with the deal’s preliminary approval. What makes this settlement unique is its extended payment schedule: the company will distribute $7.25 billion over as long as 21 years, not a lump-sum payout.
This structure means Bayer’s cash flow will remain constrained throughout the 2020s. Capital markets analysts at Capital.com project that settlement payments will result in negative free cash flow for Bayer in 2026 alone—a critical metric for dividend sustainability and shareholder returns. For investors, this means dividend cuts or suspended shareholder buybacks are possible if litigation costs continue accumulating. Class members have until June 4, 2026, to opt out of the settlement, with a final fairness hearing scheduled for July 9, 2026, so the deal is not yet final, creating lingering uncertainty.
Settlement Award Amounts and What Claimants Can Actually Expect
Not all Roundup claimants will receive equal compensation, and understanding the award structure reveals both the settlement‘s scope and its limitations. The settlement differentiates awards based on exposure history and disease severity. Agricultural workers who were under 60 years old with long-term occupational exposure and diagnosed with non-Hodgkin’s lymphoma can expect average awards of approximately $165,000. By contrast, residential users—homeowners or gardeners—aged 60 to 70 with less severe disease can expect average payments closer to $20,000. This nearly 8-fold difference highlights a critical limitation: compensation is heavily weighted toward commercial users with documented occupational exposure, not casual consumers.
Eligibility itself is narrowly defined: the settlement covers non-Hodgkin’s lymphoma diagnosed before February 17, 2026, plus future diagnoses within 16 years after court approval. However, if you were exposed to Roundup but have not yet developed non-Hodgkin’s lymphoma, you likely do not qualify under the current settlement terms. This is a major limitation for individuals concerned about future disease risk. Additionally, if new evidence emerges linking glyphosate to other cancers—such as pancreatic cancer or lung cancer—those diagnoses would fall outside this settlement’s scope entirely. The settlement does not function as a blank check for all glyphosate-related health claims; it is specifically designed to resolve past and near-future non-Hodgkin’s lymphoma cases.
The Massive Backlog of Pending Claims and Federal Litigation
Behind the $7.25 billion settlement sits a staggering caseload that illustrates why Bayer’s stock forecast remains cautious. Approximately 65,000 claims are still pending, and 3,887 lawsuits remain active in federal Roundup litigation as of March 2026. These numbers represent years of unresolved litigation, each case capable of generating jury verdicts, appeals, and additional settlement costs. Bayer has already spent more than $10 billion on Roundup settlements and defense costs—a sum that dwarfs many companies’ total annual revenues—yet litigation continues.
The pending claims vary widely in complexity and merit. Some involve claimants with strong medical documentation and clear exposure histories; others involve weaker factual records that may not survive summary judgment. Federal judges are gradually winnowing down the docket through motion practice and dismissals, but progress has been slow. For Bayer’s stock forecast, the key risk is that even after this $7.25 billion settlement, the company could still face $1 billion to $3 billion in additional settlement or judgment costs across the remaining 65,000 pending claims and federal cases. This uncertainty is why analyst price targets for Bayer stock remain depressed, with an average 12-month target of €45.29 per share (ranging from €23 to €60), compared to historical valuations before Roundup litigation exploded.
Analyst Ratings and Stock Price Targets in the Face of Litigation
Despite the massive litigation burden, Wall Street consensus on Bayer stock is not uniformly pessimistic. The mean consensus rating across major analysts is “Outperform,” suggesting that institutional investors believe Bayer’s broader pharmaceutical portfolio and agricultural business justify holding or buying the stock despite litigation headwinds. Goldman Sachs, one of the most influential investment banks, maintains a Buy rating with a €54 per share price target, reasoning that litigation containment (via the $7.25 billion settlement) and recovery of Bayer’s pharmaceutical pipeline will drive long-term value. However, there is a significant caveat: the €54 Goldman target is only 19% above the €45.29 consensus average, and that upside assumes no major adverse litigation surprises through 2026.
If the Supreme Court rules against Bayer in the *Monsanto v. Durnell* case, or if additional claims surge to federal court, those price targets could be slashed. For investors, this creates a risk-reward asymmetry: upside is capped at perhaps 20-25% in a base case, while downside could be 30-50% in a litigation-shock scenario. The wide analyst price target range (€23 to €60) reflects this deep disagreement among investors about Bayer’s litigation tail risk.
The Supreme Court Case That Could Reshape Everything
On April 27, 2026, the U.S. Supreme Court will hear oral arguments in *Monsanto v. Durnell*, a case that could fundamentally alter the trajectory of Roundup litigation nationwide. The Supreme Court’s decision, expected in the second half of June 2026, focuses on whether plaintiffs can pursue state-law tort claims against glyphosate manufacturers despite federal pesticide labeling standards. A favorable ruling for Bayer would likely eliminate a substantial portion of remaining claims by establishing that federal pesticide law preempts most state court liability suits.
Conversely, an adverse ruling would signal to plaintiffs’ attorneys that the litigation landscape remains hostile to Bayer, potentially triggering a fresh wave of federal and state court filings. For Bayer’s stock forecast, the April 27 Supreme Court argument and June decision represent the single most important event of 2026. Capital.com analysts note that a favorable ruling could add 5-10% to Bayer’s stock price within weeks, while an unfavorable ruling could trigger a 15-20% sell-off. This binary risk is precisely why many institutional investors remain on the sidelines, waiting for the Supreme Court decision before increasing Bayer positions. The challenge for investors is that Supreme Court pesticide preemption cases are notoriously unpredictable, and the Court’s 2024-2026 docket has shown little ideological consensus on regulatory preemption issues.
The Trump Administration’s Glyphosate Executive Order and Liability Shield
A less-discussed but potentially game-changing development occurred on February 18, 2026, when the Trump administration issued an executive order declaring glyphosate-based herbicides a matter of national security under the Defense Production Act. This move, reportedly aimed at protecting agricultural productivity and domestic herbicide supply chains, could theoretically shield Roundup manufacturers from certain liability claims by establishing that glyphosate regulation falls under national security authority rather than tort law. Chemical & Engineering News reported on the order’s implications for glyphosate preemption, suggesting it could influence not only ongoing litigation but also future regulatory action. However, it is uncertain whether this executive order will survive legal challenge or actually prevent existing settlements from moving forward.
The $7.25 billion settlement was negotiated before the executive order was finalized, so Bayer cannot retroactively use the national security argument to reduce settlement payments already approved. For future claims and the Supreme Court case, the executive order’s impact remains speculative. Some analysts argue it provides a political tailwind for Bayer; others contend that federal courts will view it as an executive overreach that does not legally shield companies from state-law tort claims. This ambiguity underscores a key limitation of relying on administrative action to resolve mass litigation.
What to Watch Through 2026 and the Outlook Beyond
For Bayer shareholders and settlement claimants alike, the remainder of 2026 will be decisive. Three dates frame the critical path: the June 4, 2026 opt-out deadline for the $7.25 billion settlement, the July 9, 2026 final fairness hearing, and the June 2026 Supreme Court decision in *Monsanto v. Durnell*. If the settlement wins final approval in July and the Supreme Court rules favorably in June, Bayer’s stock could re-rate substantially higher by year-end, potentially approaching the €54 Goldman Sachs target.
Conversely, if the Supreme Court rules against Bayer or if the settlement faces unexpected legal challenges, the company could spiral into a fresh litigation cycle. Looking beyond 2026, the settlement structure—with payments over 21 years—suggests that Roundup litigation will remain a material drag on Bayer’s financials through the early 2040s. Investors should monitor not only settlement payout rates but also the company’s pharmaceutical pipeline performance, as any new blockbuster drugs could offset the litigation cash drain. Claimants with pending cases should carefully track the opt-out deadline and fairness hearing dates, as a settlement collapse would return them to the uncertain dynamics of federal and state court litigation. The combination of settlement uncertainty, pending claims, and a watershed Supreme Court case makes 2026 a pivotal year for both investors and claimants alike.